Induction of Sustained Clinical Remission in Early Axial Spondyloarthritis Following Certolizumab Pegol Treatment: 48-Week Outcomes from C-OPTIMISE

by Robert Landewé, Désirée van der Heijde, Maxime Dougados, Xenofon Baraliakos, Filip Van den Bosch, Karl Gaffney, Lars Bauer, Bengt Hoepken, Natasha de Peyrecave, Karen Thomas, Lianne S. Gensler
Published 2020-06-01

Reduction of anterior uveitis flares in patients with axial spondyloarthritis on certolizumab pegol treatment: final 2-year results from the...

by Irene E. van der Horst-Bruinsma, Rianne E. van Bentum, Frank D. Verbraak, Atul Deodhar, Thomas Rath, Bengt Hoepken, Oscar Irvin-Sellers, Karen Thomas, Lars Bauer, Martin Rudwaleit
Published 2021-03-01

The impact of certolizumab pegol treatment on the incidence of anterior uveitis flares in patients with axial spondyloarthritis: 48-week interim results from C-VIEW

by Martin Rudwaleit, James T Rosenbaum, Irene van der Horst-Bruinsma, Maria Misterska-Skora, Rianne van Bentum, Frank D Verbraak, Thomas Rath, Bengt Hoepken, Oscar Irvin-Sellers, Brenda VanLunen, Lars Bauer
Published 2020-05-01